Company: MLSS
Filing Date: 2025-11-13
Form Type: 10-Q
Source: 0001493152-25-022276
Chunk: 90

Company: MILESTONE SCIENTIFIC INC.
Filing Date: 2025-11-13
Form: 10-Q
Item: Part I, Item 8
Chunk 90
---
3,027,615  
    $2,695,029  
    $332,586 
  
    Medical 
     1,234,199  
     1,411,053  
     (176,854)
  
    Corporate 
     4,764,877  
     4,862,144  
     (97,267)
  
    Total selling, general and administrative expenses 
    $9,026,691  
    $8,968,226  
    $58,465 

Consolidated selling, general, and administrative (SG&A) expenses for
the nine months ended September 30, 2025, and 2024 were approximately $9.0 million in both periods, reflecting a slight net increase of
approximately $58,000 year over year. The modest change primarily resulted from higher consulting, professional, and regulatory expenses
totaling approximately $611,000, which were largely offset by reductions in employee salaries and benefits, marketing, warehousing, and
travel expenses amounting to approximately $552,000.

The overall stability in SG&A spending demonstrates management’s
ongoing focus on expense control, operational efficiency, and resource optimization, while continuing to support the Company’s commercial
initiatives and regulatory compliance activities

Research
and Development for 2025 and 2024 were as follows:

    2025  
    2024  
    Change 
  
    Dental 
    $427,297  
    $638,226  
    $(210,929)
  
    Medical 
     9,838  
     3,009  
     6,829 
  
    Corporate 
     -  
     -  
     - 
  
    Total research and development 
    $437,135  
    $641,235  
    $(204,100)

Consolidated research and development (R&D) expenses for the nine months
ended September 30, 2025, were approximately $437,000, compared to $641,000 for the same period in 2024, representing a decrease of approximately
$204,000, or 32%. The decrease primarily reflects the Company’s decision to delay development activities related to the next-generation
STA Single Tooth Anesthesia System®.

This strategic decision allows the Company to conserve resources and prioritize
commercialization efforts for its existing product portfolio, including the continued expansion of the Compu